UNSPSC 51433802: Cilazapril

This classification denotes an ace inhibitor with the molecular formula C22H31N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Q9454114Q, chemically known as 6h-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, octahydro-9-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-10-oxo-, hydrate, (1s-(1-alpha,9-alpha(r*)))- but generally known as cilazapril, which bears US NIH Compound Identifier 56329. European Medicines Agency schedules Cilazapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06265MIG.

UNSPSC 51433802 Cilazapril, a Commodity code, encompasses emergency and critical-care medications supplied to state and local health agencies, emergency services, and pharmacy benefit programs. State and local governments procure these pharmaceutical products through competitive bidding for use by fire rescue departments, hospital systems, and multi-jurisdiction pharmacy networks. The issuing bodies span municipal purchasing departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states and localities (Minnesota Multistate Cooperative Purchasing Alliance). Vendors supplying under this code must meet FDA manufacturing compliance, maintain appropriate insurance coverage including professional and network security liability, provide comprehensive Safety Data Sheets compliant with OSHA standards, and comply with the Drug Supply Chain Security Act. Delivery timelines are typically tight—ten calendar days or less—with expiration-date warranties of nine months or longer and replacement provisions for expired stock.

Recent activity includes the City of Tampa's April 2026 sealed-bid solicitation for Advanced Life Support Medications (Bid No. 26-P-00188) requiring four specific medication line items totaling approximately 3,530 units with a $40,000 estimated contract value and a SLBE sheltered-market designation offering a 5 percent bid discount; the Minnesota Multistate Cooperative Purchasing Alliance's March 2026 RFP for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with evaluation weighted 75 percent on price competitiveness and effective July 1, 2026; and the Texas Health and Human Services Commission's April 2026 Request for Information on direct-to-manufacturer prescription capabilities to inform future procurement strategy. Recent opportunities are concentrated in the South (Florida, Texas) and Midwest (Minnesota, with Oregon participation through the cooperative), with local fire rescue and state health programs as primary customers.